Fox Chase Cancer Center

06/08/2024 | Press release | Distributed by Public on 07/08/2024 01:15

Dr. Jonathan Chernoff, Fox Chase Cancer Center Director, Named Fellow of Scientific Society

August 06, 2024
Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, has been named a Fellow of the American Society for Cell Biology.

PHILADELPHIA (August 6, 2024) - Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, has been named a Fellow of the American Society for Cell Biology (ASCB).

"Research in cell biology is such an integral part of my work in the fight against cancer," said Chernoff. "I'm incredibly humbled to have the opportunity to represent the ASCB with this new honor."

Fellowship in the ASCB is awarded based on the recipient's significant contributions to the advancement of cell biology. Approximately 20 fellows are selected annually by their peers from the society's 6,000 members. Chernoff will be recognized for this new honor at the opening session of the 2024 Cell Bio Meeting this December in San Diego.

A molecular oncologist and board-certified medical oncologist, Chernoff joined Fox Chase in 1991. In addition to helping define the strategic direction for Fox Chase research, he has made fundamental contributions in his own laboratory, which focuses on factors that control cell growth and movement, including oncogenes and anticancer or tumor-suppressor genes.

In addition to being Cancer Center Director, he also holds the Stanley P. Reimann Chair in Oncology Research and is a Professor in the Cancer Signaling and Microenvironment Research Program.

The ASCB is dedicated to scientific advancement and works to create a rich and multidisciplinary cell-centered community. Founded in 1960, the ASCB has evolved from a focus on electron microscopy to new technologies and discoveries. The ASCB includes members from undergraduates to practicing medical professionals and has included over 30 Nobel Prize recipients.

Chernoff received both his graduate and doctoral degrees in biochemistry from Mount Sinai School of Medicine in New York and his undergraduate degree in molecular biophysics and biochemistry from Yale University.

Throughout his career, Chernoff has earned a number of awards and recognitions, including being named a Fellow by the American Association for the Advancement of Science, membership in the Interurban Clinical Club, and receiving the Drug Discovery Award from the Pennsylvania Drug Discovery Institute.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427